<DOC>
	<DOCNO>NCT00264576</DOCNO>
	<brief_summary>The purpose study evaluate safety immunogenicity cell culture-derived , inactivated , subunit influenza vaccine comparison license Fluvirin vaccine administer healthy adult age 18 &lt; 50 year .</brief_summary>
	<brief_title>Study Safety Immunogenicity Influenza Vaccine Administered Healthy Adults</brief_title>
	<detailed_description />
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>18 &lt; 50 year age ; 1. able comprehend follow require study procedure ; 2. able willing provide write informed consent prior study entry ; 3. available visit schedule study ; 4. general good health determine : 1. subjectreported medical history , 2. physical examination qualify study nurse , physician 's assistant , physician , 3. clinical judgment investigator ; among female volunteer , evidence negative pregnancy test conduct day prior study vaccination , agreement practice adequate contraception least 6 week vaccination describe protocol . 1. receive influenza vaccine within past 6 month ; 2. laboratoryconfirmed influenza disease past 6 month ; 3. acute respiratory disease infection require systemic antibiotic antiviral therapy ( chronic antibiotic therapy urinary tract prophylaxis acceptable ) fever ≥38°C ( 100.4°F ) within past 3 day ; 4. receipt another investigational agent within 90 day completion safety followup period another study , whichever longer , prior enrollment , unwilling refuse participation another investigational study end study ; 5. history current serious disease , : ) cancer ( except benign localize skin cancer ) , e ) autoimmune disease ( include rheumatoid arthritis ) , f ) advance arteriosclerotic disease diabetes mellitus , g ) chronic obstructive pulmonary disease ( COPD ) , h ) acute , chronic , progressive hepatic disease , ) acute , chronic , progressive renal disease , j ) congestive heart failure , k ) bleeding diathesis , l ) inherit genetic anomaly ( know cytogenic disorder , e.g. , Down 's Syndrome ) , ) serious , acute , chronic disease include progressive neurological disease seizure disorder unrelated fever ; 6. surgery hospitalization plan study period ; 7. history anaphylaxis , serious vaccine reaction , vaccineassociated oculorespiratory syndrome , allergy egg , egg product , mercurycontaining compound ( sodiumethylmercurothiosalicylate ) , vaccine component component potential packaging material ( latex ) ; 8. know suspected disease immune system , receive immunosuppressive therapy , include use : n ) systemic corticosteroid , know associated suppression hypothalamicpituitaryadrenal ( HPA ) axis ( i.e. , systemic corticosteroid [ 15 mg/day prednisone equivalent ] chronic use inhale high potency corticosteroid [ budesonide 800 μg/day fluticasone 750 μg/day ] ) , within previous 60 day , ) receipt immunostimulants within 60 day , p ) receipt parenteral immunoglobulin preparation , blood product , and/or plasma derivative within 3 month prior study entry anticipate full length study ; 9. high risk develop immunocompromising disease ; 10. history ( current ) drug alcohol abuse investigator 's opinion would interfere safety subject evaluation study objective ; 11. pregnant breastfeeding ; 12. female childbearing potential , refusal use reliable contraceptive method , describe protocol , first 6 week vaccination ; 13. female childbearing potential sexually active , use follow birth control method specify time period prior study entry : 1. hormonal ( e.g. , oral , injection , transdermal patch , implant , cervical ring ) , barrier ( e.g. , condom spermicide diaphragm spermicide ) , intrauterine device ( e.g. , IUD ) 2 month prior study entry , 2. monogamous relationship vasectomize partner : partner vasectomize 6 month prior subject 's study entry ; 14. obese ( e.g. , body mass index [ BMI ] ≥35 , BMI reflect obesity high muscle mass ) ; 15. condition , opinion investigator , might interfere evaluation study objective might interfere safety study subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>influenza</keyword>
	<keyword>flu</keyword>
</DOC>